Sort
10,766 grants matching “checkpoint inhibitor”
Mechanisms that coordinate cell size with mitotic entry
$298,890James B Moseley · Dartmouth College · R01 · FY2015 · GM
Mechanisms of UV-induced skin carcinogenesis
$298,869Laura A Hansen · Creighton University · R01 · FY2011 · ES
Mechanisms of UV-induced skin carcinogenesis
$298,869Laura A Hansen · Creighton University · R01 · FY2012 · ES
Bifunctional Protein-Polymer Bioconjugates for Localized Melanoma Immunotherapy
$298,864Wesley Michael Jackson · Valitor, Inc. · R43 · FY2018 · CA
Pre-IND development of CBT-15 monoclonal antibody therapy against renal cell cancer
$298,835Sripathi M Sureban · Coare Holdings, Inc. · R44 · FY2018 · CA
Project 4: Immunovirotherapy
$298,617Richard G Vile · Mayo Clinic Rochester · P50 · FY2021 · CA
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
$298,566Alan R Eastman · Dartmouth College · R01 · FY2016 · CA
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
$298,566Alan R Eastman · Dartmouth College · R01 · FY2015 · CA
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
$298,566Alan R Eastman · Dartmouth College · R01 · FY2017 · CA
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS
$298,496State University Of New York At Buffalo · R01 · FY2004 · CA
Molecular Pathways in T Cell Development and Thymic Lymphoma
$298,416Harald Von Boehmer · Dana-Farber Cancer Inst · P01 · FY2008 · CA
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
$298,106Alan R Eastman · Dartmouth College · R01 · FY2013 · CA
Project 1: Imaging, pathology, and molecular biomarkers to Optimize Treatment Switching within a SMART adaptive Framework
$298,095Angela Demichele · University Of California, San Francisco · P01 · FY2024 · CA
Development of a Novel, Plasma-Based Microsatellite Instability Diagnostic for Guiding Immunotherapy
$297,850Mark Sausen · Personal Genome Diagnostics, Inc. · R43 · FY2017 · CA
The Impact of PD-1 Inhibition on Immune-Response to Chemoradiotherapy
$297,829Steven Francis Powell · Sanford Research/Usd · P20 · FY2016 · GM
The Impact of PD-1 Inhibition on Immune-Response to Chemoradiotherapy
$297,828Steven Francis Powell · Sanford Research/Usd · P20 · FY2017 · GM
PROTEOLYSIS AND MAMMALIAN GL/S CELL CYCLE TRANSITION
$297,825Yale University · R01 · FY2002 · CA
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities
$297,705Brent Allen Hanks · Duke University · R01 · FY2023 · CA
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma
$297,704Charles Keller · Children'S Cancer Therapy Develop/Inst · R01 · FY2022 · CA
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma
$297,704Charles Keller · Children'S Cancer Therapy Develop/Inst · R01 · FY2023 · CA
Mechanisms of immunomodulation with epigenetic therapy
$297,559Nilofer S. Azad · Johns Hopkins University · P01 · FY2024 · CA
Molecular targeting of the survivin pathway in cancer
$297,399Dario C. Altieri · Univ Of Massachusetts Med Sch Worcester · R01 · FY2006 · CA
Cyclin-Dependent Kinase Inhibition During S Phase
$296,988Geoffrey I Shapiro · Dana-Farber Cancer Inst · R01 · FY2014 · CA
Molecular Targeting of the Survivin Pathway in Cancer
$296,933Univ Of Massachusetts Med Sch Worcester · R01 · FY2005 · CA
Molecular Targeting of the Survivin Pathway in Cancer
$296,933Univ Of Massachusetts Med Sch Worcester · R01 · FY2004 · CA